<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509390</url>
  </required_header>
  <id_info>
    <org_study_id>9239</org_study_id>
    <nct_id>NCT02509390</nct_id>
  </id_info>
  <brief_title>Hyperfibrinogenemia After Major Trauma</brief_title>
  <official_title>Hyperfibrinogenemia Within the First Days After Major Trauma : Kinetic, Functionality, Impact of Fibrinogen Replacement Therapy and Trauma, Thrombosis Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the evolution of fibrinogen plasma level within the first ten days after major
      trauma in order to determine prevalence of hyperfibrinogenemia (Fg &gt; 4 g/L) and its time to
      onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, investigators daily investigate fibrinogen plasma levels and fibrinogen
      antigen in severe trauma patients (Injury severity score &gt; 15) within the first ten days.
      Investigators then modelize hyperfibrinogenemia profiles according to severity of injuries
      and physiopathologic mechanisms. Finally, investigators determine predisposing risk factors
      to develop hyperfibrinogenemia and assess the impact of fibrinogen replacement therapy in
      initial phase of management of major trauma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>daily fibrinogen level &gt;4 g/L</measure>
    <time_frame>10 days</time_frame>
    <description>the occurrence and delay of fibrinogen level &gt; 4 g/L after major trauma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessing predisposing risk factors of hyperfibrinogenemia (&gt; 4 g/l)</measure>
    <time_frame>10 days</time_frame>
    <description>Initial chock status severity, vascular filling, initial acidose, hypothermia, trauma severity (ISS scores, Sequential Organ Failure Assessment (SOFA), IGS2), numbers and sites of lesions (AIS scores), severity of initial failure of fibrinogene, administration of fibrinogene at initial hemorrhagic phaseâ€¦</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasmatic fibrinogen level evolution</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Major Trauma</condition>
  <arm_group>
    <arm_group_label>Severe trauma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All severe trauma patients (ISS&gt;15) admitted in our trauma center Blood samples (additional blood tubing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Investigators analyze hematological parameters with blood sampled daily in severe trauma patients</description>
    <arm_group_label>Severe trauma patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years old.

          -  Polytrauma with ISS Score &gt; 15

          -  Hospitalized patients in reanimation unit &lt; 4h after trauma

          -  Informed consent

        Exclusion Criteria:

          -  Patients in another study

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pauline PD DERAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Trauma Center, Department of Anesthesiology and critical care, Lapeyronie University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pauline PD DERAS, MD</last_name>
    <phone>+334 67 33 82 56</phone>
    <email>p-deras@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie SB BRINGUIER, PharmD</last_name>
    <phone>+334 67 33 82 56</phone>
    <email>s-bringuierbranchereau@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesiology and critical care, Lapeyronie University Hospital</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline PD DERAS, MD</last_name>
      <phone>+334 67 33 82 56</phone>
      <email>p-deras@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrinogen level</keyword>
  <keyword>Hyperfibrinogenemia</keyword>
  <keyword>Trauma</keyword>
  <keyword>Thrombosis risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

